SWHY (06806.HK): SWHY Securities Completes RMB 1.8bn Perpetual Subordinated Bonds (Tranche 3) at 1.78%
NewTimeSpace News: On 22 October 2026, Shenwan Hongyuan Group Co., Ltd. (the "Company") published an overseas regulatory announcement pursuant to Rule 13.10B of the Listing Rules, setting out the announcement released on the website of the Shenzhen Stock Exchange regarding the issuance results of the 2026 public issuance of perpetual subordinated bonds (Tranche 3) by Shenwan Hongyuan Securities Co., Ltd. to professional investors, for reference only.
The announcement disclosed that, with the consent of the China Securities Regulatory Commission under the approval on the registration of the public issuance of perpetual subordinated bonds to professional investors by Shenwan Hongyuan Securities Co., Ltd. (CSRC Permit No. [2026] 1645), Shenwan Hongyuan Securities Co., Ltd., a subsidiary of the Company, was approved to publicly issue perpetual subordinated bonds with an aggregate face value of not more than RMB 30 billion. The issuance of the 2026 perpetual subordinated bonds (Tranche 3) to professional investors was completed on 21 October 2026, with an issue size of RMB 1.8 billion and a coupon rate of 1.78%.
The Company stated that the bonds carry a floating rate, with interest calculated annually on a simple basis without compounding, remaining unchanged for the first five interest calculation years and reset every five years from the sixth interest calculation year. Each five interest calculation years constitute one repricing period, and at the end of each repricing period the issuer has the option to extend the term of the bonds by one repricing period (i.e. a further five years) or to redeem the bonds in full. The bonds are expected to be listed on the Shenzhen Stock Exchange after registration is completed.
- WUHAN YOUJI (02881.HK): Disposes Resin Workshop Assets for RMB 50.4mn and Terminates Lease; Connected Transaction
- AOM INT'L (00381.HK): Joint Venture Yingyang Smart Technology Formed with Yingyang Life Group
- HENGRUI PHARMA (01276.HK): Rezvilutamide Tablets Win Clinical Trial Approval for Prostate Cancer Phase III Study
- CMSC (06099.HK): CMSC Investment Management (HK) Guarantees CMSC International Up to HK$500mn
- CONGYU INTE AGR (00875.HK): About 139.8mn Placing Shares Placed, Net Proceeds About HK$32.9mn